Human matrix metalloproteinase 9/Gelatinase B,MMP-9 ELISA Kit

Instructions
Code CSB-E08006h
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Description

CUSABIO’s Human matrix metalloproteinase 9/Gelatinase B (MMP-9) ELISA Kit is used to quantitatively detect the concentrations of MMP-9 in human serum, plasma, tissue homogenates, cell culture supernates, or urine. This kit has been rigorously quality tested in many performances, including sensitivity, specificity, precision, recovery, linearity, and lot-to-lot consistency. It employs the sandwich ELISA mechanism and enzyme-substrate chromogenic reaction to achieve the detection. The solution color develops in proportion to the amount of MMP-9 in the sample, and the color intensity can be measured at 450 nm via a microplate reader.

MMP-9 is one of MMPs that are a family of zinc-dependent endopeptidases. Possessing type-IV collagenase activity, MMP-9 can degrade extracellular matrix (ECM) proteins to regulate ECM remodeling, cleave and release cell surface proteins, and change the cell-cell and cell-ECM interactions. MMP-9 is also involved in wound healing. Additionally, MMP-9 plays important role in cancer-related processes, including migration and invasion, metastasis, angiogenesis, and inflammation.

Target Name matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)
Alternative Names 82 kDa matrix metalloproteinase-9 ELISA Kit; 92 kDa gelatinase ELISA Kit; 92 kDa type IV collagenase ELISA Kit; CLG 4B ELISA Kit; CLG4B ELISA Kit; Collagenase Type 4 beta ELISA Kit; Collagenase type IV 92 KD ELISA Kit; EC 3.4.24.35 ELISA Kit; Gelatinase 92 KD ELISA Kit; Gelatinase B ELISA Kit; Gelatinase beta ELISA Kit; GelatinaseB ELISA Kit; GELB ELISA Kit; Macrophage gelatinase ELISA Kit; MANDP2 ELISA Kit; Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) ELISA Kit; Matrix Metalloproteinase 9 ELISA Kit; MMP 9 ELISA Kit; MMP-9 ELISA Kit; MMP9 ELISA Kit; MMP9_HUMAN ELISA Kit; Type V collagenase ELISA Kit
Abbreviation MMP9
Uniprot No. P14780
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates, cell culture supernates, urine
Detection Range 0.312 ng/mL-20 ng/mL
Sensitivity 0.284 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cancer
Assay Principle quantitative
Measurement Sandwich
Precision

 

Intra-assay Precision (Precision within an assay): CV%<8%

Three samples of known concentration were tested twenty times on one plate to assess.

Inter-assay Precision (Precision between assays):CV%<10%

Three samples of known concentration were tested in twenty assays to assess.

 

Linearity

 

To assess the linearity of the assay, samples were spiked with high concentrations of human MMP-9 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

 

Typical Data

 

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

 

Materials provided
  • A micro ELISA plate ---The 96-well plate has been pre-coated with an anti-human MMP-9 antibody. This dismountable microplate can be divided into 12 x 8 strip plates.
  • Two vials lyophilized standard ---Dilute a bottle of the standard at dilution series, read the OD values, and then draw a standard curve.
  • One vial Biotin-labeled MMP-9 antibody (100 x concentrate) (120 μl/bottle) ---Act as the detection antibody.
  • One vial HRP-avidin (100 x concentrate) (120 μl/bottle) ---Bind to the detection antibody and react with the TMB substrate to make the solution chromogenic.
  • One vial Biotin-antibody Diluent (15 ml/bottle) ---Dilute the Biotin-antibody.
  • One vial HRP-avidin Diluent (15 ml/bottle) ---Dilute the HRP-avidin solution.
  • One vial Sample Diluent (50 ml/bottle)---Dilute the sample to an appropriate concentration.
  • One vial Wash Buffer (25 x concentrate) (20 ml/bottle) ---Wash away unbound or free substances.
  • One vial TMB Substrate (10 ml/bottle) ---Act as the chromogenic agent. TMB interacts with HRP, eliciting the solution turns blue.
  • One vial Stop Solution (10 ml/bottle) ---Stop the color reaction. The solution color immediately turns from blue to yellow.
  • Four Adhesive Strips (For 96 wells) --- Cover the microplate when incubation.
  • An instruction manual
Materials not provided
  • A microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
  • An incubator can provide stable incubation conditions up to 37°C±5°C.
  • Centrifuge
  • Vortex
  • Squirt bottle, manifold dispenser, or automated microplate washer
  • Absorbent paper for blotting the microtiter plate
  • 50-300ul multi-channel micropipette
  • Pipette tips
  • Single-channel micropipette with different ranges
  • 100ml and 500ml graduated cylinders
  • Deionized or distilled water
  • Timer
  • Test tubes for dilution
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Citations

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Background

Function
(From Uniprot)
Matrix metalloproteinase that plays an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves NINJ1 to generate the Secreted ninjurin-1 form. Cleaves type IV and type V collagen into large C-terminal three quarter fragments and shorter N-terminal one quarter fragments. Degrades fibronectin but not laminin or Pz-peptide.
Gene References into Functions
  1. Cyclic peptides 1, 2, 46 also displayed potential interaction with active residues of MMP9; thus, these cyclic peptides can serve as potential drug candidates to block MMP9 activity and future studies are warranted to confirm their efficacy. PMID: 30226602
  2. Our findings indicate that monitoring serum MMP-9 and detection of histological MMP-9 could help identify TNBC patients who will respond to NAC and will display varying risks of disease relapse. MMP-9 may serve as a predictive and prognostic biomarker for tailoring and modifying the NAC strategy for TNBC. PMID: 30241470
  3. significantly increased in the serum of type 2 diabetes mellitus patients with diabetic retinopathy PMID: 29752166
  4. Study evaluated for the first time the plasma levels and the diagnostic usefulness of VEGF, MMP-9, and TIMP-1 in cervical cancer (CC), not only independently but especially in combination with established cervical tumor markers. All tested parameters showed statistical significance when compared their concentrations in patients with CC to healthy women. PMID: 30037277
  5. In monocytes, incubation with psoriasis' sera increased the production of MMP-9 and TIMP-1 in comparison with both baseline and monocytes incubated with non-psoriatic sera PMID: 29979898
  6. High mmp9 expression is associated with Endometrial adenocarcinoma. PMID: 30139240
  7. There was studied the level of matrix metalloproteinase-9 (MMP-9) in plasma of bone marrow aspirates in 87 patients: 39 with acute myeloid leukemia (AML) and 48 myelodysplastic syndrome (MDS). It has been found out an association of the level of MMP-9 in plasma of bone marrow aspirates in patients with AML and MDS with a volume of leukemic mass. PMID: 30444586
  8. This study provides the first evidence for the involvement of polymorphisms within MMP9 and the severity of childhood trauma in antipsychotic treatment response PMID: 29448178
  9. HOXD-AS1 was upregulated in non-small cell lung carcinoma tissues and cell lines and promoted NSCLC cell proliferation, migration invasion via sponging miR-133b and regulating MMP9. PMID: 29958139
  10. rs3918241, rs2250889, rs17576 and rs17577 polymorphisms of MMP-9 are not associated with altered risk of urinary cancer. PMID: 30249503
  11. PARP-1, via manipulating the binding of NF-kB/AP-1 at the MMP-9 promoter, regulates MMP-9 expression, which helps maintain mitochondrial homeostasis. PMID: 28478229
  12. The results suggest that the MMP9 gene may affect genetic predisposition to tick-borne encephalitis in a Russian population. PMID: 29496490
  13. MMP-9 was targeted by hsa-miR-494, which inhibited OS. PMID: 29068478
  14. In placenta, a significant positive correlation between MMP-9 and gestational age was noted in the first trimester. When gestational age was controlled for, partial correlation revealed a significant positive correlation between TNF-alpha and MMP-9 only in the second trimester. PMID: 28820024
  15. Melatonin inhibits epithelialtomesenchymal transition in gastric cancer cells via attenuation of IL1beta/NFkappaB/MMP2/MMP9 signaling. PMID: 30066836
  16. Data indicate that CD147 promotes breast cancer cell proliferation, metastasis, and invasion by modulating matrix metalloproteinase 9 (MMP-9) and vascular endothelial growth factor (VEGF) expression. PMID: 29901696
  17. immune system process is indispensable in the progression of disease in colon, and identifies that IL-8 and MMP-9 play potential critical roles for the progression. PMID: 30074183
  18. The demethylation of the MMP-9 gene promoter region may be involved in the occurrence and development of diabetic nephropathy by regulating the expression of MMP-9 protein in serum. PMID: 29952417
  19. Patients carrying the variant T allele of the MMP9 rs3918242 polymorphism exhibited significantly higher infarct volumes than those with the major CC genotype. PMID: 30257242
  20. Increased matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in smokers with airway hyperresponsiveness is associated with accelerated lung function decline. PMID: 29692608
  21. MMP-9 and TIMP-1 levels are correlated with age, pathological grade, tumor size and lymph node metastasis of breast cancer patients. PMID: 30010105
  22. When ANXA5 expression increased, cell proliferation was inhibited by regulating the expression of bcl-2 and bax while cell metastasis was suppressed by regulating E-cadherin and MMP-9 expression. PMID: 30010106
  23. IL-33 can regulate deposition of ECM and promote the process of pulmonary fibrosis by inducing the imbalance between MMP-9 and TIMP-1. PMID: 29417309
  24. Results show that MMP9 specifically binds to H3K27me1 nucleosomes allowing the cleavage of H3N-terminal tail. PMID: 29807539
  25. Study shows that rs1056629 polymorphism in the 3'UTR of MMP9 disrupts its binding to miR-491 in pressure ulcer (PU)patients after hip fracture. mRNA and protein expression levels are high in PU specimens. PMID: 29620239
  26. No association between the carriage of studied MMP9 polymorphisms and the predisposition to preeclampsia was found. PMID: 29670668
  27. the logistic regression analysis, none of the genes was associated with AOB (anterior open bite). In conclusion, the polymorphism rs17576 (glutamine for arginine substitution) in MMP9 was a protective factor for AOB PMID: 29297546
  28. Results provide evidence that MMP9 plays critical roles in mesenchymal stem cells high suppressive potency, which also involves the capacity to induce and integrated multiple immunoregulatory mechanisms. PMID: 28408751
  29. piperine reduced the expression of pAkt, MMP9 and pmTOR. Together, these data indicated that piperine may serve as a promising novel therapeutic agent to better overcome prostate cancer metastasis. PMID: 29488612
  30. Our study demonstrated that both positive expression status in tumor tissue and expression levels of MMP-9 are significantly elevated in BC patients and correlate with disease progression. Thus, MMP-9 can serve as a biomarker to determine the degree of BC malignancy. PMID: 29578150
  31. Our findings indicate that overexpression of MMP-9 rescued insulin survival signaling in vitro and in early stages in the 5XFAD model of AD. PMID: 28386117
  32. Review/Meta-analysis: Matrix metalloproteinase-9 has high predictive value for hemorrhagic transformation after acute ischemic stroke. PMID: 29598905
  33. The expression of MMP-9 is associated with clinical outcome in chondrosarcoma. PMID: 29316907
  34. MMP-9 levels in the tumor tissue extracts had also increased significantly PMID: 29520667
  35. MMP-9 -1562 C/T polymorphism might be related to the digestive cancer susceptibility [meta-analysis] PMID: 29890308
  36. MMP-9 protein overexpression was found in prostate cancers, low expression in any of the normal tissues or in benign prostatic tissue PMID: 27355218
  37. Hypoxia promotes retinoblastoma cell line HXO-RB44 invasion by activating HIF-1alpha/MMP9 signaling pathway. PMID: 29243776
  38. Authors conclude that ADAM8 promotes early metastatic processes such as transendothelial migration by upregulation of MMP-9 and shedding of PSGL-1 from breast cancer cells. PMID: 28986926
  39. High expression of MMP-9 and TLR4 in patients with COPD may promote inflammatory cell infiltration, induce proliferation of smooth muscle cells, degrade extracellular matrix, and play an important role in lung revascularization. PMID: 28537664
  40. The data obtained from this study show that mild hypothermia therapy down regulated the expression of MMP-9 mRNA, the MMP-9 protein level and increased the FOUR score and GCS in high-risk TBI patients within 72 h. PMID: 28966304
  41. High MMP9 expression is associated with cervical cancer. PMID: 30052166
  42. MMP-9 overexpression and activation are important events occurring during oral squamous cell carcinoma progression/invasion and that this overexpression/activation is regulated by c-Myc, active MMP-2 and inactive GSK3beta mediated pathways. PMID: 29134466
  43. Plasma concentration of MMP9 demonstrated no associations with stroke occurrence in a West African cohort. PMID: 29074065
  44. High mmp9 expression is associated with ovarian cancer cell migration and invasion. PMID: 28677781
  45. no significant difference was detected in the expression level of individual MMP9 and TIMP1 genes in SCZ patients versus healthy controls either in total numbers of subject or in sex based subgroups PMID: 28578515
  46. Data suggest that MIR129 or MIR335 overexpression in keratinocytes inhibits MMP9 promoter activity and protein expression by targeting SP1; inhibition of these microRNAs has the opposite effect. These mechanisms may be involved in regulation of wound healing. (MIR = microRNA; MMP9 = matrix metalloproteinase-9; SP1 = transcription factor-SP1) PMID: 29748291
  47. Significant association observed for MMP-9 (-1562C/T) (OR 1.27; 95% CI 1.06 to 1.53) gene polymorphism and risk of ischemic stroke. [meta-analysis] PMID: 29906531
  48. MMP-9 activity increases postpartum. Women experiencing uncomplicated vaginal delivery demonstrate higher postpartum MMP-9 activity and are more likely to have recovered their vaginal angle. PMID: 29155140
  49. Results show that MMP9 degrades MMRN2 allowing endothelial cells migration and sprouting angiogenesis. PMID: 28435016
  50. The findings suggest that AEG-1 promotes gastric cancer metastasis through upregulation of eIF4E-mediated MMP-9 and Twist. PMID: 28661037

Show More

Hide All

Involvement in disease Intervertebral disc disease (IDD); Metaphyseal anadysplasia 2 (MANDP2)
Subcellular Location Secreted, extracellular space, extracellular matrix.
Protein Families Peptidase M10A family
Tissue Specificity Detected in neutrophils (at protein level). Produced by normal alveolar macrophages and granulocytes.
Database Links

HGNC: 7176

OMIM: 120361

KEGG: hsa:4318

STRING: 9606.ENSP00000361405

UniGene: Hs.297413

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1